Search

Guanfacine

[L11277] Guanfacine was first described in the literature in 1974.[A189841] Guanfacine was granted FDA approval on 27 October 1986.[L11274] … Guanfacine, or BS 100-141,[A189838,A189841] is a selective alpha-A2 adrenergic receptor agonist initially indicated for the treatment of hypertension[L11274] but is now indicated as an extended release

Venlafaxine

[L43030] The immediate formulation of the drug, marketed as Effexor, was first approved by the FDA in 1993 and the extended-release formulation, Effexor XR, was later introduced in 1997. … Venlafaxine is an antidepressant and a serotonin and norepinephrine reuptake inhibitor (SNRI).

Levosulpiride

Dinoprostone

Dinoprostone is a naturally occurring prostaglandin E2 (PGE2). It has important effects in labour. It also stimulates osteoblasts to release factors which stimualtes bone resorption by osteoclasts.

SARS-CoV-2 Sclamp

The University of Queensland (UQ), in partnership with The Coalition for Epidemic Preparedeness Inovations (CEPI) and CSL has developed a COVID-19 candidate, SARS-CoV-2 Sclamp. … The SARS-CoV-2 Sclamp Vaccine was developed within 3 weeks and moved immediately into preclinical testing through partnership with Dutch company, Viroclinics Xplore.

Hydrocodone

Hydrocodone's more potent metabolite, [hydromorphone] has also found wide use as an analgesic and is frequently used in cases of severe pain. … [T116] It is commonly used in combination with [acetaminophen] to control moderate to severe pain.

BNT162a1 SARS-CoV-2 Vaccine

[L15002, L15007] BNT162a1 is undergoing evaluation in clinical trials in both the USA (NCT04368728) and Germany (NCT04380701).[L15017, L15022] … [L15002, L15007] BNT162a1 is a uridine mRNA (uRNA) vaccine formulated in lipid nanoparticles for delivery via intramuscular injection.

BNT162c2 SARS-CoV-2 Vaccine

[L15002, L15007] BNT162c2 is undergoing evaluation in clinical trials in both the USA (NCT04368728) and Germany (NCT04380701).[L15017, L15022] … [L15002, L15007] BNT162c2 is a self-amplifying mRNA (saRNA) vaccine formulated in lipid nanoparticles for delivery via intramuscular injection.

Nimesulide

Due to concerns about the risk of hepatotoxicity, nimesulide has been withdrawn from market in many countries. … Its approved indications are the treatment of acute pain, the symptomatic treatment of osteoarthritis and primary dysmenorrhoea in adolescents and adults above 12 years old.

Anti-SARS-CoV-2 immunoglobulin

[L27521] Anti-coronavirus immunoglobulin is derived from [COVID-19 convalescent plasma](https://go.drugbank.com/drugs/DB15692) but contains more SARS-CoV-2 neutralizing antibodies than found in [convalescent … Hyperimmune immunoglobulin to SARS-CoV-2 (hIVIG) is obtained from the plasma of patients who recover from COVID-19 and develop neutralizing antibodies.